Agrin, a unique growth factor for cartilage regeneration in osteoarthritis
Agrin, a unique growth factor for cartilage regeneration in osteoarthritis
批准号:
MR/R000956/1
负责人:
Francesco Dell'Accio
金额:
$60.48万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2018
资助国家:
英国
项目状态:
已结题
起止时间:
2018 至 --
中文摘要
关节软骨是覆盖长骨末端的组织,其允许关节的无摩擦运动。关节软骨的损失,这是骨关节炎的主要特征,导致关节疼痛和无法行走或执行简单的任务。骨关节炎是英国残疾津贴的主要原因,并与巨大的间接费用有关。它影响到超过三分之一的60岁以上的人口,因此是影响福祉的主要因素之一,特别是老年人。迄今为止,我们没有任何治疗方法可以阻止骨关节炎的进展。可用的治疗方法仅限于止痛药和关节置换。虽然关节置换术通常有效,但在多达五分之一的患者中,关节置换术达不到患者的期望,并且寿命有限,通常需要复杂且具有挑战性的翻修手术。由于人们的寿命更长,而且越来越多的人在更早的年龄患上骨关节炎,关节置换术的这种严重局限性变得更加突出。我们发现,一种由软骨细胞产生的叫做聚集蛋白的分子对软骨健康至关重要。在骨关节炎中,这种分子被降解,但是我们知道给予聚集蛋白将有助于形成新的软骨,并且还将限制软骨降解分子如MMP-3的产生。最后,我们发现聚集蛋白的作用方式之一是通过关闭一种名为WNT的分子信号,这种分子信号已被证明有利于软骨分解,并且当过度活跃时,使人容易患上骨关节炎。在这项研究中,我们打算测试是否确实将聚集蛋白直接施用到关节中可以治疗骨关节炎。首先,我们将对老鼠进行基因工程改造,这样当我们服用一种特殊的药物时,聚集蛋白就会在软骨中产生。这将确保聚集蛋白在软骨内以最佳方式递送,并且我们看到的任何效果都是由于聚集蛋白对软骨的影响。我们将通过损伤膝关节的半月板来诱导这些小鼠的骨关节炎,这会导致机械性关节不稳定。半月板损伤是骨关节炎发展的常见原因,也在人。一旦小鼠患上骨关节炎,我们将给予特殊的药物,诱导软骨中的聚集蛋白产生。我们将观察与对照组相比,软骨中的聚集蛋白诱导是否会导致骨关节炎的愈合。除了这种仅在软骨中导致聚集蛋白产生增加的遗传方法外,我们还将使用诱导聚集蛋白产生的病毒,或在发炎组织中不能降解的聚集蛋白的较小片段。这些病毒将被注射到关节中,就像合成的聚集蛋白在患者体内一样。因此,聚集蛋白不仅会进入软骨,而且会进入其他关节组织,如骨骼和称为滑膜的关节内衬。最后,我们将从分子水平研究Agrin激活软骨细胞的机制。这一目标的实现将使我们能够鉴定出已经存在的化合物,这些化合物可以激活相同途径的相同受体和细胞组分,并使我们能够在不必合成聚集蛋白的情况下实现相同的效果。
英文摘要
The articular cartilage is the tissue that covers the ends of the long bones and that allows the frictionless motion of the joint. The loss of the articular cartilage, which is the main feature of osteoarthritis, leads to joint pain and incapacity to walk or perform simple tasks. Osteoarthritis is the leading cause for disability allowance in UK and is associated with huge indirect costs. It affects over 1/3 of the population over the age of 60 and therefore is one of the major factors affecting well-being particularly in the elderly. To-date, we do not have any treatment that stops progression of osteoarthritis. Available treatments are limited to pain killers and joint replacement. Although generally effective, joint replacement does not live up to the patients' expectations in up to one in five patients, and has a limited life span often requiring complex and challenging revision surgery. This serious limitation of joint replacement is becoming more prominent due to the fact that people live much longer and because more people are developing osteoarthritis at an earlier age. We have discovered that a molecule called Agrin, produced by cartilage cells, is essential for cartilage health. In osteoarthritis this molecule is degraded, however we know that administering Agrin will help forming new cartilage and will also limit the production of cartilage-degrading molecules such as MMP-3. Finally, we have discovered that one way that Agrin works is by shutting down a molecular signal called WNT which has been shown to favour cartilage breakdown and, when excessively active, predisposes people to develop osteoarthritis.In this study we intend to test if indeed administering Agrin directly into the joint can treat osteoarthritis. First, we will genetically engineer mice so that Agrin is produced within cartilage when we administer a special drug. This will ensure that Agrin is delivered optimally within the cartilage and that whatever effect we see is due to the effect of Agrin on cartilage. We will induce osteoarthritis in these mice by damaging the meniscus in the knee, which results in mechanical joint instability. Damage to the meniscus is a common cause of osteoarthritis development also in people. Once the mice have developed osteoarthritis we will administer the special drug that will induce Agrin production in the cartilage. We will then see if, compared to controls, Agrin induction in cartilage leads to healing of osteoarthritis.In addition to this genetic approach which leads to increased Agrin production only in cartilage, we will use also viruses that induce the production of Agrin, or smaller fragments of Agrin that cannot be degraded in inflamed tissues. These viruses will be injected into the joint just like synthetic Agrin would be in patients. Therefore Agrin will go not only into cartilage, but also into other joint tissues such as the bone and the internal lining of the joint called synovial membrane. This will enable to see the effects of Agrin administration to all tissues of the joint.Finally, using molecular approaches, we will study the mechanism by which Agrin activates cartilage cells. The delivery of this aim will enable us to identify already existing compounds that can activate the same receptor and cellular components of the same pathway and may enable us to achieve the same effects without having to make synthetic Agrin.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
A Mouse Model of Acute Cartilage Injury and Repair.
急性软骨损伤和修复的小鼠模型。
DOI:
10.1007/978-1-0716-2839-3_24
发表时间:
2023
期刊:
Methods in molecular biology (Clifton, N.J.)
影响因子:
--
作者:
[Thorup AS]
通讯作者:
Thorup AS
DOI:
10.15252/emmm.202216218
发表时间:
2023-01-11
期刊:
EMBO molecular medicine
影响因子:
11.1
作者:
[]
通讯作者:
DOI:
10.1002/jev2.12088
发表时间:
2021-05
期刊:
Journal of extracellular vesicles
影响因子:
16
作者:
[Thomas BL, Eldridge SE, Nosrati B, Alvarez M, Thorup AS, Nalesso G, Caxaria S, Barawi A, Nicholson JG, Perretti M, Gaston-Massuet C, Pitzalis C, Maloney A, Moore A, Jupp R, Dell'Accio F]
通讯作者:
Dell'Accio F
DOI:
10.1002/art.41421
发表时间:
2020-11-04
期刊:
ARTHRITIS & RHEUMATOLOGY
影响因子:
13.3
作者:
[von Loga, Isabell S., Batchelor, Vicky, Vincent, Tonia L.]
通讯作者:
Vincent, Tonia L.
Function of CXCR2 signalling within the articular cartilage
-
批准号:MR/N010973/1
-
项目类别:Research Grant
-
资助金额:$61.88万
-
财政年份:2016
-
负责人:Francesco Dell'Accio
-
依托单位:
Targeting WNT/CaMKII in Osteoarthritis
-
批准号:MR/K013076/1
-
项目类别:Research Grant
-
资助金额:$38.64万
-
财政年份:2013
-
负责人:Francesco Dell'Accio
-
依托单位:
国内基金
海外基金
微分动力系统的测度和熵
-
批准号:11101447
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:孙鹏
-
依托单位: